Terminated NA INTERVENTIONAL NCT00233051

Evaluating Genes in Sputum to Measure Drug Response in COPD

Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD

Sponsor: GlaxoSmithKline

Conditions Chronic Bronchitis Chronic Obstructive Pulmonary Disease (COPD) Emphysema

Interventions Salmeterol or Salmeterol/Fluticasone

Updated 6 times since 2017 Last updated: Mar 27, 2017 Started: Apr 30, 2003 Primary completion: Jun 30, 2006 Completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from GlaxoSmithKline

See all terminations from GlaxoSmithKline

Other Chronic Bronchitis trials with similar outcome

Browse all Chronic Bronchitis trials

Listed as NCT00233051, this NA trial focuses on Chronic Bronchitis and Chronic Obstructive Pulmonary Disease (COPD) and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Apr 2017 — Jun 2018 [monthly]

Terminated NA

▶ Show 1 earlier version

Jan 2017 — Apr 2017 [monthly]

Terminated NA

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
National Jewish Health

Data source: National Jewish Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Denver, United States